Endoscopy & Procedures · Article 172

How Should Warfarin Be Managed for Colonoscopy and Polypectomy?

Warfarin colonoscopy requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Warfarin colonoscopy clinical reference — Related free clinical resource: Endoscopy and Diagnostic Imaging.

Warfarin colonoscopy: practical clinical approach

This page focuses on Warfarin colonoscopy with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Warfarin colonoscopy

Clinical takeaway: For Warfarin colonoscopy, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Warfarin can often be continued for low-risk endoscopic procedures. For higher-risk polypectomy or advanced resection, interruption may be appropriate depending on thromboembolic risk. The 2022 ACG-CAG guideline generally suggests against routine heparin bridging when warfarin is held because bridging increases bleeding without clear benefit in most patients. Patients with very high thromboembolic risk, such as selected mechanical-valve situations, require individualized cardiology/hematology input.

Low-risk procedures often do not require interruption

Diagnostic colonoscopy and mucosal biopsy generally have low bleeding risk.

High-risk resection changes the balance

Large hot-snare polypectomy, EMR and ESD may justify temporary interruption.

Bridging is the exception

Most atrial-fibrillation patients do not benefit from heparin bridging.

Practical clinical algorithm

1. Confirm warfarin indication and thrombotic risk.

2. Classify the planned procedure.

3. Continue warfarin for appropriate low-risk procedures.

4. If interruption is needed, stop for the appropriate interval and confirm INR when required.

5. Avoid routine bridging.

6. Restart once procedural hemostasis is adequate.

Common mistakes to avoid

Bridging every atrial-fibrillation patient.
Stopping warfarin for diagnostic procedures unnecessarily.
Ignoring mechanical-valve risk.
Failing to confirm INR when a high-risk intervention is planned.
Delaying restart without reason.

Trainee takeaway

Warfarin decisions should be driven by procedure risk and thromboembolic risk; bridging is no longer a default.

Frequently asked questions

Can biopsy be done on warfarin?

Often yes, depending on INR and local guidance.

Who might still need bridging?

Selected very-high-risk patients, particularly some mechanical-valve scenarios.

When is warfarin usually restarted?

Often the day of or soon after the procedure once hemostasis is secure.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Endoscopy and Diagnostic Imaging. Part I. CAPstone Academic Publishers; 2012.

3. Abraham NS, et al. ACG-CAG Clinical Practice Guideline. Am J Gastroenterol. 2022;117:542-558.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions